Completed PHASE3 INTERVENTIONAL NCT00293917

A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis

A Phase 3, Long-Term, Open Label Study to Evaluate the Safety of Twice Daily Tacrolimus Cream-B 0.1% in the Treatment of Psoriasis

Sponsor: Astellas Pharma Inc

Conditions Psoriasis

Interventions Tacrolimus Cream

Updated 6 times since 2017 Last updated: Feb 11, 2008 Started: Jan 31, 2006 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Psoriasis, this trial is completed. The trial is conducted by Astellas Pharma Inc and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
Astellas Pharma US, Inc.

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Atlanta, United States , Bellingham, United States , Birmingham, United States , Boise, United States , Boston, United States , Chicago, United States , Detroit, United States , East Setauket, United States , East Windsor, United States and 25 more locations